Loading provider…
Loading provider…
Surgery Physician in Raleigh, NC
NPI: 1649469610Primary Practice Location
DUKE UNIVERSITY HOSPITAL
2301 Erwin Rd, Durham, NC
Primary Employer
Duke Health Integrated Practice, Inc.
dhip.dukehealth.org
HQ Phone
Get M.D. Sabino's Phone Numberphone_androidMobile
Get M.D. Sabino's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCT State Medical License
NC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 73 | 93 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 51 | 51 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 16 | 19 |
| 4 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 13 | 19 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 12 | 12 |
Robotic Inguinal Hernia Repair (TAPP) First Experience with the New Senhance Robotic System.
Authors: Justin Barr, Michael Scheidt
Journal: Surg Technol Int
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.
Authors: Nancy Kemeny, Diane Reidy-Lagunes, Louise Catherine Connell, Jeffrey Drebin, T Kingham, Kevin Soares, William Jarnagin, Alice Wei, Michael Lidsky, Ghassan Abou-Alfa, Vinod Balachandran, Jeremy Sharib, Michael D'Angelica, James Harding, Hope Uronis, John Strickler
Publication Date: 2025-04
Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.
Authors: Jin He, Jeffrey Drebin, Richard Burkhart, Lei Zheng, T Kingham, Kevin Soares, Shannon Radomski, William Jarnagin, Alice Wei, Mengyuan Liu, Michael Lidsky, Vinod Balachandran, Alex Blair
Journal: Ann Surg Oncol
Publication Date: 2024-11-22
Lead Sponsor: Delcath Systems Inc.
Intervention / Treatment: COMBINATION_PRODUCT: Melphalan/HDS, DRUG: Cisplatin and Gemcitabine